Study 1 of 12Liraglutide literatureLancet (London, England)Top journal2026
Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity.
Not reported in abstract.
Where it sits
this study against the rest of the liraglutide corpus3
Preclinical · this one
5
Observational
0
Open-label
2
Randomised
2
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.00). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Liraglutide corpus
AA systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults: 2026 Updatebiorxiv-preprint · 2026 · Not reported in abstract.HumanBComparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetes Mellitusbiorxiv-preprint · 2026 · meta-analytic HR 1.05 for 3-point MACE (95% CI 0.79-1.39)HumanBCLINICAL CHARACTERISTICS OF USERS OF WEIGHT LOSS DRUGS: POPULATION-BASED CASE-CONTROL STUDYbiorxiv-preprint · 2026 · 4,603 liraglutide users identified during 2023-2024.HumanBRisk of Allodynia with GLP-1 Agonistsbiorxiv-preprint · 2026 · aHR 2.15 (95% CI 1.57–2.96)HumanAGlucagon-like peptide-1 receptor agonist-induced lipidome remodelling is associated with improved liver, kidney and inflammatory markers in type 2 diabetesbiorxiv-preprint · 2026 · Not reported in abstract.HumanBFall Reporting with GLP-1 Receptor Agonists in Older Adults: A FDA Adverse Event Reporting System (FAERS) Disproportionality Analysisbiorxiv-preprint · 2026 · ROR for falls was 2.75 (95% CI 2.47–3.06).Human